Du C, Mao X, Xu Y, Yan Y, Yuan C, Du X, Liu J, Fan H, Wang Q, Sui W, Deng S, Fu M, Li Z, Li C, Zhao J, Yi S, Liu L, Hao M, Zou D, Zhao Y, Qiu L, An G. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib. Leuk Lymphoma. 2020;61(5):1201-1210.
Yan Y, Lv, Xiong W, Li Z, Wang Y, Yu Y, Yu Z, Wang T, Sui W, Liu W, Zou D, Yi S, Qiu L. Subtype distribution, clinical features and survival in B-cell chronic lymphoproliferative disorders in China: a review of 1592 cases, Clinical Lymphoma, Myeloma and Leukemia, 2019 7. pii: S2152-2650(19)32099-3.
Yi# S, Yan# Y, Xiong W, Lv R, Yu Z, Liu W, Liu E, Li H, Liu H, Li Z, An G, Xu Y, Ru K, Zou D, Qiu L. Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region, Oncotarget, 2017 19;8(58):98757-98770. (Equal contributor)
Yan Y, Mao X, Liu J, Fan H, Du C, Li Z, Yi S, Wang T, Lv R, Liu W, Deng S, Sui W, Wang Q, Zou D, Cheng T, Zhan F, Tai Y-T, Qiu L, Anderson KC, Gang A. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Advances. 2019 8;3(19):2895-2904.
An# G, Yan# Y, Xu Y, Mao X, Liu J, Fan H, Wang Q, Du C, Li Z, Yi S, Lv R, Deng S, Sui W, Fu M, Hao M, Huang W, Zou D, zhao Y, Cheng T, Tai Y-T, Munshi N, Qiu L. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia, 2020;34(2):578-588. (Equal contributor)